Related Experiment Videos
Intrathecal ziconotide for refractory pain
1Doggrell Biomedical Communications, 47 Caronia Crescent, Lynfield, Auckland, New Zealand. s.doggrell@xtra.co.nz
Expert Opinion on Investigational Drugs
|June 24, 2004
Summary
Ziconotide shows promise for managing refractory pain in cancer and AIDS patients, significantly improving pain scores. However, serious adverse effects necessitate further research for optimal use.
Area of Science:
- Neuroscience
- Pharmacology
- Oncology
Background:
- Refractory pain affects 10-30% of cancer and AIDS patients, often requiring intraspinal drug administration.
- Current opioid therapies are insufficient for managing severe, persistent pain in these populations.
Purpose of the Study:
- To evaluate the efficacy and safety of ziconotide for refractory pain management.
- To compare ziconotide's effectiveness against placebo in patients with unmanaged pain.
Main Methods:
- A clinical trial involving 108 patients with refractory pain.
- Initial titration phase comparing ziconotide to placebo.
- Maintenance phase for patients continuing ziconotide treatment.
Main Results:
- Ziconotide group showed a 53% improvement in Visual Analogue Scale of Pain Intensity scores versus 18% in the placebo group during titration.
- Serious adverse effects were more frequent in the ziconotide group (31%) compared to placebo (10%).
- Continued benefit was observed in patients receiving ziconotide during the maintenance phase.
Conclusions:
- Ziconotide demonstrates significant efficacy in reducing refractory pain.
- The adverse effect profile requires careful consideration and management.
- Further optimization of ziconotide therapy is warranted until superior alternatives emerge.